News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
722,118 Results
Type
Article (46855)
Company Profile (295)
Press Release (674968)
Multimedia
Podcasts (68)
Webinars (12)
Section
Business (209288)
Career Advice (2190)
Deals (36021)
Drug Delivery (114)
Drug Development (82363)
Employer Resources (191)
FDA (16368)
Job Trends (15258)
News (352687)
Policy (33260)
Tag
Academia (2743)
Academic (2)
Accelerated approval (5)
Adcomms (23)
Allergies (88)
Alliances (51009)
ALS (97)
Alzheimer's disease (1429)
Antibody-drug conjugate (ADC) (139)
Approvals (16359)
Artificial intelligence (285)
Autoimmune disease (23)
Automation (16)
Bankruptcy (366)
Best Places to Work (11826)
BIOSECURE Act (20)
Biosimilars (108)
Biotechnology (201)
Bladder cancer (79)
Brain cancer (27)
Breast cancer (293)
Cancer (2341)
Cardiovascular disease (185)
Career advice (1838)
Career pathing (33)
CAR-T (163)
Cell therapy (454)
Cervical cancer (21)
Clinical research (66800)
Collaboration (885)
Company closure (2)
Compensation (558)
Complete response letters (21)
COVID-19 (2670)
CRISPR (43)
C-suite (258)
Cystic fibrosis (102)
Data (2311)
Decentralized trials (2)
Denatured (32)
Depression (45)
Diabetes (277)
Diagnostics (6531)
Digital health (18)
Diversity (9)
Diversity, equity & inclusion (47)
Drug discovery (123)
Drug pricing (111)
Drug shortages (26)
Duchenne muscular dystrophy (99)
Earnings (87850)
Editorial (42)
Employer branding (25)
Employer resources (161)
Events (116163)
Executive appointments (756)
FDA (17744)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (794)
Gene editing (114)
Generative AI (22)
Gene therapy (325)
GLP-1 (765)
Government (4581)
Grass and pollen (4)
Guidances (150)
Healthcare (19201)
Huntington's disease (26)
IgA nephropathy (29)
Immunology and inflammation (128)
Indications (29)
Infectious disease (2817)
Inflammatory bowel disease (148)
Inflation Reduction Act (10)
Influenza (52)
Intellectual property (99)
Interviews (346)
IPO (16732)
IRA (42)
Job creations (3845)
Job search strategy (1570)
Kidney cancer (10)
Labor market (46)
Layoffs (497)
Leadership (19)
Legal (8070)
Liver cancer (77)
Lung cancer (332)
Lymphoma (157)
Machine learning (9)
Management (62)
Manufacturing (333)
MASH (75)
Medical device (13538)
Medtech (13543)
Mergers & acquisitions (19858)
Metabolic disorders (726)
Multiple sclerosis (84)
NASH (22)
Neurodegenerative disease (96)
Neuropsychiatric disorders (27)
Neuroscience (1994)
NextGen: Class of 2025 (6717)
Non-profit (4650)
Now hiring (41)
Obesity (390)
Opinion (223)
Ovarian cancer (82)
Pain (94)
Pancreatic cancer (89)
Parkinson's disease (154)
Partnered (21)
Patents (244)
Patient recruitment (117)
Peanut (48)
People (59346)
Pharmaceutical (71)
Pharmacy benefit managers (19)
Phase I (20807)
Phase II (29410)
Phase III (21906)
Pipeline (1352)
Policy (151)
Postmarket research (2643)
Preclinical (9083)
Press Release (72)
Prostate cancer (108)
Psychedelics (32)
Radiopharmaceuticals (252)
Rare diseases (390)
Real estate (6228)
Recruiting (72)
Regulatory (22768)
Reports (56)
Research institute (2477)
Resumes & cover letters (374)
Rett syndrome (5)
RNA editing (5)
RSV (44)
Schizophrenia (74)
Series A (139)
Series B (90)
Service/supplier (14)
Sickle cell disease (55)
Special edition (17)
Spinal muscular atrophy (150)
Sponsored (30)
Startups (3782)
State (2)
Stomach cancer (14)
Supply chain (69)
Tariffs (48)
The Weekly (34)
Vaccines (726)
Venture capitalists (44)
Weight loss (255)
Women's health (38)
Worklife (18)
Date
Today (160)
Last 7 days (937)
Last 30 days (3118)
Last 365 days (32999)
2025 (11872)
2024 (35947)
2023 (40860)
2022 (51924)
2021 (56499)
2020 (54898)
2019 (47646)
2018 (35936)
2017 (33085)
2016 (32665)
2015 (38767)
2014 (32375)
2013 (27536)
2012 (29798)
2011 (30535)
2010 (29032)
Location
Africa (794)
Alabama (55)
Alaska (7)
Arizona (242)
Arkansas (14)
Asia (39559)
Australia (6508)
California (6438)
Canada (2069)
China (540)
Colorado (279)
Connecticut (279)
Delaware (157)
Europe (86052)
Florida (951)
Georgia (221)
Hawaii (1)
Idaho (58)
Illinois (562)
India (27)
Indiana (327)
Iowa (11)
Japan (172)
Kansas (108)
Kentucky (26)
Louisiana (12)
Maine (62)
Maryland (933)
Massachusetts (4809)
Michigan (241)
Minnesota (419)
Mississippi (2)
Missouri (82)
Montana (27)
Nebraska (25)
Nevada (68)
New Hampshire (65)
New Jersey (1807)
New Mexico (30)
New York (1821)
North Carolina (1029)
North Dakota (9)
Northern California (2825)
Ohio (211)
Oklahoma (14)
Oregon (34)
Pennsylvania (1428)
Puerto Rico (13)
Rhode Island (33)
South America (1172)
South Carolina (25)
South Dakota (1)
Southern California (2419)
Tennessee (106)
Texas (959)
United States (24263)
Utah (193)
Virginia (153)
Washington D.C. (69)
Washington State (569)
West Virginia (3)
Wisconsin (67)
722,118 Results for "cassava sciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Alzheimer’s disease
Cassava Finally Ends Alzheimer’s Program for Embattled Simufilam
After years of controversy and allegations of doctored data, Cassava is moving on from Alzheimer’s.
March 25, 2025
·
1 min read
·
Annalee Armstrong
Collaboration
Cassava’s Stock Rises After Licensing Seizure Rights for Embattled Drug Simufilam
The licensing deal follows years of controversy for Cassava, as well as the high-profile late-stage failure of its Alzheimer’s disease drug simufilam.
February 28, 2025
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
Cassava’s Shares Plunge as Alzheimer’s Drug Fails Phase III
Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had pledged to share the results whether “good, bad or ambiguous.”
November 25, 2024
·
2 min read
·
Annalee Armstrong
Press Releases
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
March 26, 2025
·
9 min read
Press Releases
Cassava Sciences Licenses Simufilam Method of Treatment Patent
February 28, 2025
·
6 min read
Press Releases
Cassava Sciences Reports 2024 Financial Results and Provides Business Update
March 4, 2025
·
12 min read
Press Releases
Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC
May 2, 2025
·
6 min read
Press Releases
Cassava Reports Q1 2025 Financials Results, Provides Business Update
May 8, 2025
·
9 min read
Podcast
BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for Amvuttra in the indication; Cassava’s controversial Alzheimer’s drug flunks Phase III; Amgen’s MariTide fails to impress investors, Donald Trump’s controversial nominations continue.
November 27, 2024
·
1 min read
·
Heather McKenzie
Press Releases
Cassava Sciences Provides a Business Update - January 7, 2025
January 8, 2025
·
8 min read
1 of 72,212
Next
